Stockreport

Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. [Read more]